International Journal of Pharmacology and Clinical Research (IJPCR) https://ijpcr.net/ijpcr <p><strong><em>International Journal of Pharmacology and Clinical Research (IJPCR) </em></strong>is a peer-reviewed, quarterly official international journal allowing access to abstracts<strong>&nbsp;</strong>and<strong>&nbsp;</strong>full-text. The journal is devoted to the promotion of pharmaceutical sciences and related disciplines (Pharmacology, Biopharmaceutics, Pharmacokinetics, Pharmaceutical Medicinal Chemistry, Computational Chemistry &amp; Molecular Drug Design, Pharmacognosy &amp; Phytochemistry, Pharmaceutical Analysis, Pharmacy Practice, Clinical &amp; Hospital Pharmacy, Cell Biology, Genomics &amp; Proteomics, Pharmacogenomics, Bioinformatics including biotechnology, cell &amp; molecular biology, Pharmaceutical biotechnology/microbiology, medical and other life sciences).</p> <p><strong>ISSN</strong>&nbsp;-&nbsp;<strong><em>International Journal of Pharmacology and Clinical Research (IJPCR)</em></strong></p> <p><strong>Online</strong>:<strong>&nbsp;</strong>2521-2206</p> <p><strong><em>International Journal of Pharmacology and Clinical Research </em></strong>seeks to foster multidisciplinary research and collaboration among scientists, pharmaceutical industries and healthcare sector as well as provide an international forum for the communication and evaluation of data, methods and opinions in pharmaceutical sciences and related disciplines. Although primarily devoted to original research papers, the journal particularly welcomes reviews on current topics of special interest and relevance. All manuscripts will be subjected to rapid peer review. Those of high quality (not previously published and not already under consideration for publication) will be published.</p> en-US ijpcreditor@gmail.com (Dr.N.Sriram) drnsriram@gmail.com (Dr.N.Sriram) Mon, 15 Apr 2024 17:45:49 +0000 OJS 3.1.2.4 http://blogs.law.harvard.edu/tech/rss 60 Advances in Understanding and Treating Schizophrenia: A Comprehensive Review https://ijpcr.net/ijpcr/article/view/579 <p>Schizophrenia is a debilitating psychiatric disorder characterized by psychotic symptoms, including hallucinations and delusions, which profoundly impact emotions, behavior, and cognition. Its global prevalence underscores its significance as a public health concern, with substantial social and economic burdens. The pathophysiology of schizophrenia implicates dysregulation of neurotransmitters, particularly dopamine, serotonin, and glutamate. Schizophrenia is a complex psychiatric disorder characterized by a wide range of symptoms and cognitive impairments, profoundly impacting affected individuals and society. This article provides an overview of schizophrenia, including its epidemiology, symptoms, and underlying pathophysiology involving dopamine, serotonin, and glutamate. It discusses the current treatment landscape, emphasizing the importance of both pharmacological and non-pharmacological interventions. Non-pharmacological approaches such as cognitive remediation, physical exercise, non-invasive brain stimulation, complementary interventions, cognitive behavioral therapy, and yoga therapy are explored, highlighting their efficacy in improving functional outcomes. Additionally, the article reviews pharmacological strategies targeting dopamine, serotonin, and glutamate receptors, as well as emerging treatments involving adrenergic, cholinergic, muscarinic, and other agents. Despite advancements, challenges in implementing evidence-based interventions persist, underscoring the need for further research and collaboration to enhance schizophrenia management and improve the lives of affected individuals.</p> Amna Hameed Thayyil, Zeenath P, Aiswarya Lakshmi P, E Tamil Jothi , G Babu, Anson S Maroky Copyright (c) https://ijpcr.net/ijpcr/article/view/579 Mon, 15 Apr 2024 00:00:00 +0000